The role of magnetic resonance imaging in the diagnosis of cardiac amyloidosis
https://doi.org/10.51922/2616-633X.2025.9.1.2491
Abstract
Cardiac amyloidosis is characterized by extracellular deposition of abnor- mal proteins in the myocardium. A manifestation of cardiac amy- loidosis is the rapid progression of heart failure and the development of life-threatening arrhythmias, atrial fibrillation, and embolic strokes.
The diagnosis of cardiac amyloidosis should be excluded in all patients with rapidly progressive heart failure associated with a restrictive remodeling phenotype in combination with myocardial hypertrophy. Cardiac magnetic resonance imaging (MRI) is considered to be an accurate and specific diagnostic method. This article reviews the diagnostic MR-criteria for cardiac amyloidosis and provides confirmed clinical cases.
About the Authors
H. D. Model
Republican Scientific and Practical Center of Cardiology
Belarus
Belarus
Minsk
T. V. Нorbat
Republican Scientific and Practical Center of Cardiology
Belarus
Belarus
Minsk
T. V. Rusak
Republican Scientific and Practical Center of Cardiology
Belarus
Belarus
Minsk
References
1. Oda S., Kidoh M., Nagayama Y. et al. Trends in Diagnostic Imaging of Cardiac Amyloidosis: Emerging Knowledge and Concepts. RadioGraphics, 2020, vol. 40, pp. 961–981. doi: org/10.1148/rg.2020190069.
2. Tereshchenko S.N., Zhirov I.V., Moiseeva O.M. et al. Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). Terapevticheskii arkhiv, 2022, vol 94(4), pp. 584–595. doi: 10.26442/00403660.2022.04.201465. (in Russian).
3. Baker K.R. Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication. Methodist Debakey. Cardiovasc J. 2022, vol. 18(2), pp. 27–35. doi: 10.14797/mdcvj.1070.
4. Dorbala S., Ando Y., Bokhari S., et al. ASNC/AHA/ASE/EANM/ HFSA/ISA/SCMR/ SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2– evidence base and standardized methods of imaging. J Nucl Cardiol, 2019, vol. 26(6), pp. 2065–2123. doi:10.1007/s12350-019-01760-6.
5. Garcia-Pavia P., Rapezzi C., Adler Y. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, vol. 42(16), pp 1554–1568. doi: 10.1093/eurheartj/ehab072.
6. Dorbala S., Cuddy S., Falk R.H. How to Image Cardiac Amyloidosis: A Practical Approach. JACC Cardiovasc Imaging, 2020, vol. 13(6), pp. 1368–1383. doi: 10.1016/j.jcmg.2019.07.015.
Review
For citations:
Model H.D., Нorbat T.V., Rusak T.V. The role of magnetic resonance imaging in the diagnosis of cardiac amyloidosis. Emergency Cardiology and Cardiovascular Risks journal. 2025;9(1):2491-2496. (In Russ.) https://doi.org/10.51922/2616-633X.2025.9.1.2491
Views:
49
Email this article 